-
The 2022 ESMO Roundtable sent Professor Lu Shun to lead a team of experts to talk about immunity
Time of Update: 2023-01-07
The European Society for Medical Oncology (ESMO) Congress is a prestigious and influential oncology conference in Europe, and the ESMO Congress 2022 has successively announced many innovative therapie
-
J Clin Oncol: Neoadjuvant Nivolumab/Ipilimumab + Adjuvant Nivolumab in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma
Time of Update: 2022-10-15
In conclusion, for patients with dMMR/MSI-H resectable gastric/gastroesophageal junction adenocarcinoma, nivolumab- and ipilimumab-based neoadjuvant therapy is feasible, with a high pathological complete response rate and no Unexpected toxicity .
-
A new breakthrough in CAR-T cell therapy: successfully treating multiple patients with lupus erythematosus and achieving long-term drug-free remission
Time of Update: 2022-10-03
Written by Editor Wang DuoyuTypesettingWater into writingSystemic lupus erythematosus (SLE) is a severe autoimmune disease with an incidence of 0. 1% in the general population and mainly affects young
-
Eight big rumors of "what to eat and what to make up
Time of Update: 2022-09-26
Rumor Six: Eat waist to supplement kidneys?Pig loin, is one of the internal organs of animals, although it contains high nutrients such as protein, cholesterol, vitamins and trace elements, but the purine, cholesterol and fat content in the waist flower are high, and a large amount of eating will cause a burden on the kidneys.
-
Why don't immune cells attack gut microbes? Nature reveals key clues
Time of Update: 2022-09-21
In a new study published in Nature on September 8, Beijing time, a research team from Cornell University's Weill Cornell School of Medicine found that a class of congenital lymphocytes plays an important role in establishing tolerance to symbiotic microorganisms in the human gastrointestinal tract.
-
Introduction to the classification of tumor research models and the advantages and applications of tumor organoids
Time of Update: 2022-08-30
Tumor organoids recapitulate typical features of patient-specific tumor heterogeneity [1] Tumor research model competitionPatient-derived tumor organoids (PDOs) can complement the shortcomings of 2D cell and mouse xenograft cancer models (PDX), offering great promise for optimizing preclinical drug discovery .
-
Nature Immunology: Regulators of the immune system
Time of Update: 2022-05-19
In this study, immunologists led by Penn veterinarian Professor Christopher Hunter and doctoral student Joseph Perry found that blocking the activity of the checkpoint PD-L1 protein, which interacts with the T cell receptor PD-1, enhances the growth of T cells The activity of a subset is called effector regulatory T cells, or effector subsets .
-
AACR 2022: NK Cells and Bispecific Antibody AFM13 Complexes Consistently Induce Lymphoma Remission
Time of Update: 2022-05-18
The complex of the bispecific antibody AFM13 with NK cells continued to induce remission in patients with relapsed CD30 + lymphoma , results from a phase I/II study presented Sunday at the American Association for Cancer Research (AACR) annual meeting .
-
COVID-19 vaccine NVX-CoV2373 nearly 80% effective in adolescents
Time of Update: 2022-03-02
Pharmaceutical company Novavax today announced that its protein -based COVID-19 vaccine, NVX-CoV2373, demonstrated near 80% efficacy in adolescent participants in the pivotal PREVENT-19 trial .
Pharmaceutical company Novavax today announced that its protein -based COVID-19 vaccine, NVX-CoV2373, demonstrated near 80% efficacy in adolescent participants in the pivotal PREVENT-19 trial .
-
Muyuan shares: overdue bills did not affect the company's financing
Time of Update: 2021-12-27
On December 7th, in a conference call organized by a listed company, Muyuan responded to many hot issues, including the impact of overdue bills on the company’s financing, the basis for applying for a credit line of 70 billion yuan next year, and the current progress of the financial company’s preparations, etc.
-
Nature's heavyweight: CAR-T treatment of solid tumors welcomes a major breakthrough, a new generation of therapy may become a cancer killer
Time of Update: 2021-12-04
surface peptides, and can be used for children " of peptide-center " chimeric antigen receptor ( "peptide-centric" antigen chimeric receptors , the PC-the CAR for targeted), this new type of CAR-T cells capable of stimulating an immune reaction , And after testing in mice, it showed the therapeutic effect of complete tumor regression .
-
Clin Trans Gastroenterology: Indomethacin does not relieve the systemic inflammatory response syndrome of acute pancreatitis
Time of Update: 2021-11-12
The purpose of this study was to compare the efficacy of rectal indomethacin and placebo in reducing systemic inflammatory response syndrome (SIRS) scores in high-risk AP populations .
-
J Autoimmun: The relationship between patients with autoimmune rheumatism and COVID-19 infection
Time of Update: 2021-11-02
immunityMethods: In this observational study, the demographic data, disease-related characteristics and comorbidities, manifestations and outcomes of COVID-19, and response to SARS-CoV-2 were recorded for 77 patients with potential AARD who were continuously infected with SARS-CoV-2.
-
Br J Cancer: ICI pretreatment with immune checkpoint inhibitor improves the efficacy of dacarbazine in the treatment of metastatic melanoma
Time of Update: 2021-08-02
Some previous observational studies have shown that chemotherapy has improved the efficacy of melanoma or lung cancer patients who have previously received ICI treatment .
69 months), while the median PFS of patients who did not receive ICI treatment was 2.
-
Lancet Infect Dis: The safety and immunogenicity of the SARS-CoV-2 inactivated vaccine BBIBP-CorV
Time of Update: 2021-07-29
Recently, a randomized, double-blind, placebo-controlled trial conducted in Henan, China evaluated the safety of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) candidate vaccine BBIBP-CorV in humans and immune immunogenicity results Infect Dis has been published in the Lancet .
